Search

Home > New FDA Approvals > 015 - FDA approves GSK's Shingrix; Astra Zeneca's Bydureon BCise (exenatide new formulation) approved for Type 2 diabetes; DBV's phase III peanut allergy treatment fails to meet endpoint
Podcast: New FDA Approvals
Episode:

015 - FDA approves GSK's Shingrix; Astra Zeneca's Bydureon BCise (exenatide new formulation) approved for Type 2 diabetes; DBV's phase III peanut allergy treatment fails to meet endpoint
Category: Science & Medicine
Duration: 0
Publish Date: 2017-10-23 06:00:00
Description:

October 23, 2017

0:29 Shingrix approved in the US for prevention of shingles in adults aged 50 and over

https://www.gsk.com/en-gb/media/press-releases/shingrix-approved-in-the-us-for-prevention-of-shingles-in-adults-aged-50-and-over/

 

2:15 New formulation of once-weekly exenatide in an improved device provides significant HbA1c reduction with added benefit of weight losshttps://www.astrazeneca.com/media-centre/press-releases/2017/us-fda-approves-new-easy-to-use-once-weekly-bydureon-bcise-injectable-medicine-for-patients-with-type-2-diabetes-231017.html

 

4:12 DBV announced Phase III data, with their treatment unable to mark a statistically significant separation from a placebo arm as defined by the trial protocol.https://media.dbv-technologies.com/d286/ressources/_pdf/5/4257-PR-PEPITES-topline-results-FINAL.pdf

Please visit us at nascentmc.com or email info@nascentmc.com if we can assist with any medical writing needs!

 
Total Play: 0